
Giovanni Lanza

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4963060/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Epigenetic Regulation: A Link between Inflammation and Carcinogenesis. Cancers, 2022, 14, 1221.	1.7	15
2	Nothing but lung and bones: Longitudinal evolution and quantitative analysis in a case of idiopathic diffuse pulmonary ossification. Radiology Case Reports, 2022, 17, 1340-1344.	0.2	0
3	Detection of diseaseâ€causing mutations in prostate cancer by NGS sequencing. Cell Biology International, 2022, 46, 1047-1061.	1.4	10
4	Inflammatory Microenvironment in Early Non-Small Cell Lung Cancer: Exploring the Predictive Value of Radiomics. Cancers, 2022, 14, 3335.	1.7	5
5	Sera from Patients with Malignant Pleural Mesothelioma Tested Positive for IgG Antibodies against SV40 Large T Antigen: The Viral Oncoprotein. Journal of Oncology, 2022, 2022, 1-9.	0.6	1
6	Mitochondrial Ca2+ Signaling in Health, Disease and Therapy. Cells, 2021, 10, 1317.	1.8	59
7	Evaluation of a Nep-Score Threshold and the Derived Nep-D Score in Predicting Survival of Patients With Typical and Atypical Bronchial Carcinoids. Journal of the Endocrine Society, 2021, 5, A1017-A1018.	0.1	Ο
8	SARS-CoV-2 nucleocapsid protein and ultrastructural modifications in small bowel of a 4-week-negative COVID-19 patient. Clinical Microbiology and Infection, 2021, 27, 936-937.	2.8	20
9	The histomorphological and molecular landscape of colorectal adenomas and serrated lesions. Pathologica, 2021, 113, 218-229.	1.3	8
10	Lateâ€onset intrauterine growth restriction and HHVâ€6 infection: A pilot study. Journal of Medical Virology, 2021, 93, 6317-6322.	2.5	7
11	Successful fenofibrate therapy for severe and persistent hypertriglyceridemia in a boy with cirrhosis and glycerolâ€3â€phosphate dehydrogenase 1 deficiency. JIMD Reports, 2020, 54, 25-31.	0.7	9
12	Histopathological grading affects survival in patients with IDH-mutant grade II and grade III diffuse gliomas. European Journal of Cancer, 2020, 137, 10-17.	1.3	25
13	Therapeutic potential of FLANC, a novel primate-specific long non-coding RNA in colorectal cancer. Gut, 2020, 69, 1818-1831.	6.1	80
14	Molecular testing on bronchial washings for the diagnosis and predictive assessment of lung cancer. Molecular Oncology, 2020, 14, 2163-2175.	2.1	20
15	Detection of DNA Mismatch Repair Protein Abnormalities in Sudanese Colorectal Cancer Patients Using Immunohistochemical Methods. Journal of Gastrointestinal Cancer, 2019, 50, 530-536.	0.6	2
16	Molecular biomarkers predicting early development of endometrial carcinoma: A pilot study. European Journal of Cancer Care, 2019, 28, e13137.	0.7	9
17	SLUG/HIF1-α/miR-221 regulatory circuit in endometrial cancer. Gene, 2019, 711, 143938.	1.0	14
18	Class 1, 2, and 3 <i>BRAF</i> -Mutated Metastatic Colorectal Cancer: A Detailed Clinical, Pathologic, and Molecular Characterization. Clinical Cancer Research, 2019, 25, 3954-3961.	3.2	67

GIOVANNI LANZA

#	Article	IF	CITATIONS
19	miR-224 Is Significantly Upregulated and Targets Caspase-3 and Caspase-7 During Colorectal Carcinogenesis. Translational Oncology, 2019, 12, 282-291.	1.7	14
20	Umbilical nodules: two cases of atypical cutaneous endometriosis. Italian Journal of Dermatology and Venereology, 2019, , .	0.1	0
21	Clinico-pathological and molecular characterization of BRAF mutant metastatic colorectal cancer (mCRC): Are all mutations created equal?. Annals of Oncology, 2018, 29, v58.	0.6	1
22	P3.03-22 IL-1β as a New Early Predictive Biomarker for Non-Small Cell Lung Cancers Outcome. Journal of Thoracic Oncology, 2018, 13, S918.	0.5	0
23	The role of clinical and molecular factors in low-grade gliomas: what is their impact on survival?. Future Oncology, 2018, 14, 1559-1567.	1.1	17
24	Evaluation of the Role of <i>BRAF</i> V600E Somatic Mutation on Papillary Thyroid Cancer Disease Persistence: A Prospective Study. European Thyroid Journal, 2018, 7, 251-257.	1.2	11
25	Clinico-pathological and molecular characterisation of BRAF mutant metastatic colorectal cancer (mCRC): Are all mutations created equal?. Journal of Clinical Oncology, 2018, 36, 3590-3590.	0.8	4
26	Role of <i>MGMT</i> Methylation Status at Time of Diagnosis and Recurrence for Patients with Glioblastoma: Clinical Implications. Oncologist, 2017, 22, 432-437.	1.9	61
27	Merkel Cell Carcinomas Arising in Autoimmune Disease Affected Patients Treated with Biologic Drugs, Including Anti-TNF. Clinical Cancer Research, 2017, 23, 3929-3934.	3.2	55
28	N-BLR, a primate-specific non-coding transcript leads to colorectal cancer invasion and migration. Genome Biology, 2017, 18, 98.	3.8	97
29	Double inhibition of cAMP and mTOR signalling may potentiate the reduction of cell growth in ADPKD cells. Clinical and Experimental Nephrology, 2017, 21, 203-211.	0.7	16
30	Proposal for a novel management of indeterminate thyroid nodules on the basis of cytopathological subclasses. Endocrine, 2017, 57, 98-107.	1.1	10
31	Gender and MGMT methylation in glioblastoma patients: interactions in the PERNO prospective study. Annals of Oncology, 2017, 28, vi75.	0.6	0
32	Histologic and sonographic features of holmium laser in the treatment of chronic venous disease. International Angiology, 2017, 36, 122-128.	0.4	1
33	BRAF mutation and Microsatellite status in stage II and III colorectal cancers: does the combination have a prognostic role?. Annals of Oncology, 2016, 27, iv44.	0.6	0
34	An apparently untreatable ulcer of the face. International Wound Journal, 2016, 13, 1084-1086.	1.3	0
35	PML at Mitochondria-Associated Membranes Is Critical for the Repression of Autophagy and Cancer Development. Cell Reports, 2016, 16, 2415-2427.	2.9	127
36	Relapses of primary cutaneous anaplastic large-cell lymphoma in a female immunocompetent patient with persistent chlamydophila pneumoniae and human herpesvirus 8 infection. Infectious Agents and Cancer, 2016, 11, 31.	1.2	4

GIOVANNI LANZA

#	Article	IF	CITATIONS
37	Allele-Specific Reprogramming of Cancer Metabolism by the Long Non-coding RNA CCAT2. Molecular Cell, 2016, 61, 520-534.	4.5	142
38	The clinical and biological significance of MIR-224 expression in colorectal cancer metastasis. Gut, 2016, 65, 977-989.	6.1	111
39	Preoperative endoscopic tattooing to mark the tumour site does not improve lymph node retrieval in colorectal cancer: a retrospective cohort study. Journal of Negative Results in BioMedicine, 2015, 14, 9.	1.4	11
40	Genomic Classifier ColoPrint Predicts Recurrence in Stage II Colorectal Cancer Patients More Accurately Than Clinical Factors. Oncologist, 2015, 20, 127-133.	1.9	109
41	Gene Expression Changes in Progression of Cervical Neoplasia Revealed by Microarray Analysis of Cervical Neoplastic Keratinocytes. Journal of Cellular Physiology, 2015, 230, 806-812.	2.0	49
42	Relevance of BRAFV600E Mutation Testing Versus RAS Point Mutations and RET/PTC Rearrangements Evaluation in the Diagnosis of Thyroid Cancer. Thyroid, 2015, 25, 221-228.	2.4	43
43	A New Case of Syringocystadenocarcinoma Papilliferum: A Rare Pathology for a Wide-Ranging Comprehension. Case Reports in Medicine, 2014, 2014, 1-8.	0.3	14
44	Pattern of care and effectiveness of treatment for glioblastoma patients in the real world: Results from a prospective population-based registry. Could survival differ in a high-volume center?. Neuro-Oncology Practice, 2014, 1, 166-171.	1.0	23
45	Differential expression of microRNA501â€5p affects the aggressiveness of clear cell renal carcinoma. FEBS Open Bio, 2014, 4, 952-965.	1.0	16
46	Eosinophilic Gastroenteritis Cured with <i>Helicobacter pylori</i> Eradication: Case Report and Review of Literature. Helicobacter, 2014, 19, 237-238.	1.6	5
47	P.12.7 THIRD ROUND OF COLORECTAL CANCER SCREENING IN FERRARA (2009–2011): PREVALENCE OF COLORECTAL CANCER AND ADVANCED ADENOMA AND COMPARISON WITH A 2-YEAR PRESCREENING PERIOD (2003–2005). Digestive and Liver Disease, 2014, 46, S100.	0.4	0
48	MicroRNA-135b Promotes Cancer Progression by Acting as a Downstream Effector of Oncogenic Pathways in Colon Cancer. Cancer Cell, 2014, 25, 469-483.	7.7	267
49	Identification of miRNAs Differentially Expressed in Human Epilepsy with or without Granule Cell Pathology. PLoS ONE, 2014, 9, e105521.	1.1	36
50	<i>CCAT2</i> , a novel noncoding RNA mapping to 8q24, underlies metastatic progression and chromosomal instability in colon cancer. Genome Research, 2013, 23, 1446-1461.	2.4	526
51	microRNA-135b promotes cancer progression acting as a downstream effector of oncogenic pathways in colon cancer. Lancet, The, 2013, 381, S17.	6.3	3
52	The stimulation of A3 adenosine receptors reduces bone-residing breast cancer in a rat preclinical model. European Journal of Cancer, 2013, 49, 482-491.	1.3	40
53	Downregulation of the Mitochondrial Calcium Uniporter by Cancer-Related miR-25. Current Biology, 2013, 23, 58-63.	1.8	198
54	Segmented Filamentous Bacteria-Like Organisms in Histological Slides of Ileo-Cecal Valves in Patients with Ulcerative Colitis. American Journal of Gastroenterology, 2013, 108, 860-861.	0.2	29

GIOVANNI LANZA

#	Article	IF	CITATIONS
55	Strand-Specific miR-28-5p and miR-28-3p Have Distinct Effects in Colorectal Cancer Cells. Gastroenterology, 2012, 142, 886-896.e9.	0.6	174
56	Gastrointestinal Stromal Tumors and Other Malignancies: a Case Series. Journal of Gastrointestinal Cancer, 2012, 43, 634-637.	0.6	13
57	Loss of cortical GABA terminals in Unverricht–Lundborg disease. Neurobiology of Disease, 2012, 47, 216-224.	2.1	42
58	Clinical and technical validation of a genomic classifier (ColoPrint) for predicting outcome of patients with stage II colon cancer Journal of Clinical Oncology, 2012, 30, 384-384.	0.8	8
59	Anti-miR-135b in colon cancer treatment: Results from a preclinical study Journal of Clinical Oncology, 2012, 30, 457-457.	0.8	2
60	Colorectal tumors: The histology report. Digestive and Liver Disease, 2011, 43, S344-S355.	0.4	30
61	P.1.251: THE FIRST TWO YEARS OF COLORECTAL CANCER SCREENING IN THE FERRARA DISTRICT, ITALY. Digestive and Liver Disease, 2011, 43, S231-S232.	0.4	0
62	The first 2 years of colorectal cancer screening in Ferrara, Italy. European Journal of Cancer Prevention, 2011, 20, 166-168.	0.6	4
63	MicroRNA profiling for the identification of cancers with unknown primary tissueâ€ofâ€origin. Journal of Pathology, 2011, 225, 43-53.	2.1	117
64	Modulation of mismatch repair and genomic stability by miR-155. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 6982-6987.	3.3	306
65	Oncogenic Role of <i>miR-483-3p</i> at the <i>IGF2/483</i> Locus. Cancer Research, 2010, 70, 3140-3149.	0.4	272
66	Abstract 2087: miR-483-3p is an oncogene involved in nephroblastoma and in adult tumors with activated β-catenin. , 2010, , .		0
67	The methylator phenotype in microsatellite stable colorectal cancers is characterized by a distinct gene expression profile. Journal of Pathology, 2008, 214, 594-602.	2.1	47
68	MicroRNA involvement in hepatocellular carcinoma. Journal of Cellular and Molecular Medicine, 2008, 12, 2189-2204.	1.6	248
69	PA.128 PATHOLOGIC FEATURES OF COLORECTAL CANCERS DETECTED BY POPULATION SCREENING IN THE PROVINCE OF FERRARA. Digestive and Liver Disease, 2008, 40, S121.	0.4	ο
70	Nidogen 1 and 2 gene promoters are aberrantly methylated in human gastrointestinal cancer. Molecular Cancer, 2007, 6, 17.	7.9	64
71	mRNA/microRNA gene expression profile in microsatellite unstable colorectal cancer. Molecular Cancer, 2007, 6, 54.	7.9	240
72	Ultraconserved Regions Encoding ncRNAs Are Altered in Human Leukemias and Carcinomas. Cancer Cell, 2007, 12, 215-229.	7.7	681

Giovanni Lanza

#	Article	IF	CITATIONS
73	Identification and Classification of Hereditary Nonpolyposis Colorectal Cancer (Lynch Syndrome): Adapting Old Concepts to Recent Advancements. Report from the Italian Association for the Study of Hereditary Colorectal Tumors Consensus Group. Diseases of the Colon and Rectum, 2007, 50, 2126-2134.	0.7	12
74	A microRNA expression signature of human solid tumors defines cancer gene targets. Proceedings of the United States of America, 2006, 103, 2257-2261.	3.3	5,220
75	Immunohistochemical Test for MLH1 and MSH2 Expression Predicts Clinical Outcome in Stage II and III Colorectal Cancer Patients. Journal of Clinical Oncology, 2006, 24, 2359-2367.	0.8	197
76	Adjuvant Chemotherapy in Colorectal Cancer Patients with Microsatellite Instability. Clinical Cancer Research, 2006, 12, 3866-3867.	3.2	2
77	Microsatellite Instability and Colorectal Cancer Prognosis. Clinical Cancer Research, 2005, 11, 8332-8340.	3.2	339
78	Frequent Aberrant Methylation of the CDH4 Gene Promoter in Human Colorectal and Gastric Cancer. Cancer Research, 2004, 64, 8156-8159.	0.4	96
79	Elevated Expression of A3 Adenosine Receptors in Human Colorectal Cancer Is Reflected in Peripheral Blood Cells. Clinical Cancer Research, 2004, 10, 5895-5901.	3.2	404
80	Multigene Methylation Analysis of Gastrointestinal Tumors. Molecular Diagnosis and Therapy, 2003, 7, 201-207.	1.2	18
81	Multigene Methylation Analysis of Gastrointestinal Tumors. Molecular Diagnosis and Therapy, 2003, 7, 201-207.	1.2	33
82	Immunohistochemical Pattern of MLH1/MSH2 Expression Is Related to Clinical and Pathological Features in Colorectal Adenocarcinomas with Microsatellite Instability. Modern Pathology, 2002, 15, 741-749.	2.9	103
83	Microsatellite Instability in Colorectal Cancer: Prognostic, Predictive or Both?. American Journal of Pathology, 2002, 160, 384-386.	1.9	1
84	Long-Term Insulin Independence following Repeated Islet Transplantation in Totally Pancreatectomized Diabetic Pigs. Cell Transplantation, 2002, 11, 55-66.	1.2	19
85	Microsatellite Instability and High Content of Activated Cytotoxic Lymphocytes Identify Colon Cancer Patients with a Favorable Prognosis. American Journal of Pathology, 2001, 159, 297-304.	1.9	275
86	Fhit protein expression in human gastric cancer and related precancerous lesions. Oncology Reports, 2001, 8, 1233-7.	1.2	6
87	Sporadic colorectal adenocarcinomas with high-frequency microsatellite instability. Cancer, 2000, 89, 2025-2037.	2.0	195
88	Genetic progression in microsatellite instability high (MSI-H) colon cancers correlates with clinico-pathological parameters: A study of theTGRβRII,BAX,hMSH3,hMSH6,IGFIIR andBLM genes. International Journal of Cancer, 2000, 89, 230-235.	2.3	101
89	Sporadic colorectal adenocarcinomas with highâ€frequency microsatellite instability. Cancer, 2000, 89, 2025-2037.	2.0	5
90	Genetic progression in microsatellite instability high (MSIâ€H) colon cancers correlates with clinicoâ€pathological parameters: A study of the TGRRII, BAX, hMSH3, hMSH6, IGFIIR and BLM genes. International Journal of Cancer, 2000, 89, 230-235.	2.3	4

Giovanni Lanza

#	Article	IF	CITATIONS
91	Medullary-Type Poorly Differentiated Adenocarcinoma of the Large Bowel: A Distinct Clinicopathologic Entity Characterized by Microsatellite Instability and Improved Survival. Journal of Clinical Oncology, 1999, 17, 2429-2429.	0.8	92
92	Microsatellite instability in multiple colorectal tumors. International Journal of Cancer, 1999, 81, 1-5.	2.3	72
93	Prognostic significance of DNA ploidy in patients with stage II and stage III colon carcinoma. Cancer, 1998, 82, 49-59.	2.0	66
94	Chromosome 18q allelic loss and prognosis in stage II and III colon cancer. , 1998, 79, 390-395.		126
95	p53 Expression in Colorectal Cancer:Relation to Tumor Type, DNA Ploidy Pattern, and Short-Term Survival. American Journal of Clinical Pathology, 1996, 105, 604-612.	0.4	58
96	Biologic Characterization of Hereditary Non-Polyposis Colorectal Cancer: <i>Nuclear Ploidy, AgNOR Count, Microvessel Distribution, Oncogene Expression, and Grade-Related Parameters</i> . American Journal of Clinical Pathology, 1995, 103, 265-270.	0.4	28
97	Immunohistochemical Assessment of Growth Fractions in Colorectal Adenocarcinomas with Monoclonal Antibody Ki-67. Pathology Research and Practice, 1990, 186, 608-618.	1.0	22
98	Monoclonal Antibodies for Specific Immunoperoxidase Detection of Campylobacter pylori. Gastroenterology, 1989, 96, 414-420.	0.6	45
99	ras p21 oncoprotein expression in human colonic neoplasia?an immunohistochemical study with monoclonal antibody RAP-5. Histopathology, 1988, 12, 595-609.	1.6	12
100	Colonic mucosa adjacent to adenomas and hyperplastic polyps?a morphological and histochemical study. Histopathology, 1985, 9, 857-873.	1.6	19
101	Morphologic Changes, Mucin Secretion, Carcinoembryonic Antigen (Cea) and Peanut Lectin Reactivity in Colonic Mucosa of Patients at High Risk for Colorectal Cancer. Tumori, 1984, 70, 539-548.	0.6	7
102	In vivo and in vitro immunofluorescent approach to the physiopathology of estradiol kinetics in target cells. The Journal of Steroid Biochemistry, 1976, 7, 883-890.	1.3	25
103	Detection and dynamic localisation of estradiol-receptor complexes in intact target cells by immunofluorescence technique. The Journal of Steroid Biochemistry, 1976, 7, 505-510.	1.3	92
104	Extranodal localization of non-Hodgkin's lymphoma in systemic sclerosis: A diagnostic challenge and review of the literature. Journal of Scleroderma and Related Disorders, 0, , 239719832210884.	1.0	0